PATENT CLAIM ANALYSIS

Application Number: 15991326
Application Type: Utility
Filing Date: 2018-05
Publication Date: 2019-02
Patent Classification: ["514", "04400A"]

Abstract:
The present invention relates to antisense oligonucleotides (oligomers) that are complementary to HTRA1, leading to modulation of the expression of HTRA1. Modulation of HTRA1 expression is beneficial for a range of medical disorders, such as macular degeneration, e.g. age-related macular degeneration.

Claim (Index 8):
The antisense oligonucleotide according to any one of  claims 1 - 7 , where the contiguous nucleotide region of the oligonucleotide comprises at least one modified internucleoside linkage, such as one or more phosphorothioate internucleoside linkages, or such as all the internucleoside linkages within the contiguous nucleotide region are phosphorothioate internucleoside linkages.

Metadata:
- Claim Count in Document: 5.0
- Percentile: 93.0
- Lexical Diversity: 1.4
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['15635629', '15971951', '14897223', '15971970', '15836144']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7741853575759207
- 35 USC 102 Novelty (BERT): 0.6237004781056917
- Combined Prediction Score: 0.7591368696288978
- Mean Citation Score: 424.386488
- Max Citation Score: 602.95087
- Similarity Product: 493.1776326297354

Labels:
- Claim Label 101: 1
- Claim Label 102: 0
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 0
- Label 101 Adjusted: 0

Dataset: test